MA29966B1 - Traitement des tumeurs neuroendocrines - Google Patents

Traitement des tumeurs neuroendocrines

Info

Publication number
MA29966B1
MA29966B1 MA30950A MA30950A MA29966B1 MA 29966 B1 MA29966 B1 MA 29966B1 MA 30950 A MA30950 A MA 30950A MA 30950 A MA30950 A MA 30950A MA 29966 B1 MA29966 B1 MA 29966B1
Authority
MA
Morocco
Prior art keywords
treatment
neuroendocrine tumors
tumors
administration
possibly
Prior art date
Application number
MA30950A
Other languages
English (en)
Inventor
Peter Wayne Marks
David Lebwohl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29966(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0523658A external-priority patent/GB0523658D0/en
Priority claimed from GB0601082A external-priority patent/GB0601082D0/en
Priority claimed from GB0602747A external-priority patent/GB0602747D0/en
Priority claimed from GB0607942A external-priority patent/GB0607942D0/en
Priority claimed from GB0609272A external-priority patent/GB0609272D0/en
Priority claimed from GB0609912A external-priority patent/GB0609912D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29966B1 publication Critical patent/MA29966B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN PROCÉDÉ DE TRAITEMENT DES TUMEURS ENDOCRINES, QUI COMPREND L'ADMINISTRATION D'UN INHIBITEUR DE MTOR, ÉVENTUELLEMENT EN ASSOCIATION AVEC UN AUTRE MÉDICAMENT.
MA30950A 2005-11-21 2008-05-20 Traitement des tumeurs neuroendocrines MA29966B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0523658A GB0523658D0 (en) 2005-11-21 2005-11-21 Organic compounds
GB0601082A GB0601082D0 (en) 2006-01-19 2006-01-19 Organic Compounds
GB0602747A GB0602747D0 (en) 2006-02-10 2006-02-10 Organic compounds
GB0607942A GB0607942D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0609272A GB0609272D0 (en) 2006-05-10 2006-05-10 Organic compounds
GB0609912A GB0609912D0 (en) 2006-05-18 2006-05-18 Organic compounds
EP06120660 2006-09-14

Publications (1)

Publication Number Publication Date
MA29966B1 true MA29966B1 (fr) 2008-11-03

Family

ID=37671355

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30950A MA29966B1 (fr) 2005-11-21 2008-05-20 Traitement des tumeurs neuroendocrines

Country Status (21)

Country Link
US (3) US9006224B2 (fr)
EP (3) EP2275103B1 (fr)
JP (3) JP2009516671A (fr)
KR (2) KR20140012218A (fr)
CN (1) CN103446138A (fr)
AU (2) AU2006314444C1 (fr)
BR (1) BRPI0618808A2 (fr)
CA (2) CA2933875C (fr)
CY (1) CY1115299T1 (fr)
DK (1) DK2275103T3 (fr)
ES (1) ES2481671T3 (fr)
HR (1) HRP20140708T1 (fr)
IL (3) IL191475A (fr)
MA (1) MA29966B1 (fr)
NO (4) NO346575B1 (fr)
NZ (1) NZ568182A (fr)
PL (1) PL2275103T3 (fr)
PT (1) PT2275103E (fr)
RU (1) RU2487711C2 (fr)
SI (1) SI2275103T1 (fr)
WO (1) WO2007057457A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2762140T (lt) 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
JP2009532503A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2278966B1 (fr) 2008-03-21 2019-10-09 The University of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
WO2010151517A2 (fr) 2009-06-25 2010-12-29 The Regents Of The University Of Michigan Lymphocytes t mémoire spécifiques d'un antigène
EP3354652B1 (fr) 2010-03-10 2020-05-06 Incyte Holdings Corporation Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1
KR101978537B1 (ko) * 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
JP2016516671A (ja) * 2013-02-28 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤を用いたがんの治療
WO2014144405A1 (fr) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Utilisation d'inhibiteurs de mtor pour la prévention du développement et de la croissance d'une tumeur neuroendocrine
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
WO2017000085A1 (fr) * 2015-06-30 2017-01-05 上海交通大学 Utilisation de sunlidac dans la préparation d'un produit de lutte contre le cancer du poumon
IL311974A (en) * 2016-01-21 2024-06-01 Amryt Endo Inc Somatostatin receptor ligands such as octreotide for oral administration to treat the disease
WO2018204477A1 (fr) * 2017-05-02 2018-11-08 Cornell University Procédés et réactifs pour ciblage de tumeur avec une efficacité améliorée et une toxicité réduite
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
US20210024542A1 (en) * 2018-02-09 2021-01-28 Torcept Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of cancer
CN118978535A (zh) 2018-05-01 2024-11-19 锐新医药公司 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
CA3098698A1 (fr) 2018-05-01 2019-11-07 Revolution Medicines, Inc. Analogues de rapamycine lies a c26 utilises en tant qu'inhibiteurs de mtor
WO2020041329A1 (fr) * 2018-08-20 2020-02-27 Yale University Polythérapie pour le traitement ou la prévention de la dépression ou d'autres maladies de l'humeur
WO2020191002A1 (fr) * 2019-03-18 2020-09-24 The Regents Of The University Of California Compositions et procédés pour le traitement d'une maladie de cushing
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3220332A1 (fr) * 2021-06-07 2022-12-15 Nanopharmaceuticals Llc Composition et methode de double ciblage dans le traitement de tumeurs neuroendocrines
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
EP4525836A4 (fr) 2022-05-18 2026-02-25 Hadasit Medical Res Services&Development Ltd Combinaison d'endocannabinoïdes et d'inhibiteurs de mtor dans le traitement de néoplasmes neuroendocriniens
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB9013448D0 (en) 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP0836605B1 (fr) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines et leurs procedes de preparation
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
DE69719320T2 (de) * 1996-06-11 2003-12-11 Novartis Ag, Basel Kombination eines somatostatin analogs und eines rapamycins
EP0907642B1 (fr) 1996-06-24 2005-11-02 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
US5932613A (en) 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
EP1107964B8 (fr) 1998-08-11 2010-04-07 Novartis AG Derives d'isoquinoline possedant une activite d'inhibition de l'angiogenese
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
EP2016953A3 (fr) 1998-12-22 2009-04-15 Genentech, Inc. Antagonistes de facteur de croissance cellulaire endothéliale vasculaire et utilisations associées
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
RU2264405C2 (ru) 1999-12-06 2005-11-20 Новартис Аг 40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
SG159378A1 (en) 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
CN1309421C (zh) * 2001-04-06 2007-04-11 惠氏公司 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
WO2002098416A2 (fr) * 2001-06-01 2002-12-12 Wyeth Combinaisons antineoplasiques
US20030008923A1 (en) 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
US20060094674A1 (en) 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2004052359A1 (fr) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Procede d'inhibition selective de la janus tyrosine kinase 3 (jak3)
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
MXPA06007174A (es) 2003-12-22 2006-08-23 Novartis Ag Biomarcadores para determinar la sensibilidad de enfermedades proliferativas a inhibidores mtor.
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
BRPI0507834A (pt) 2004-02-23 2007-07-10 Sugen Inc método para tratar o crescimento celular anormal usando inibidores de c-met e de m-tor
US7749698B2 (en) 2004-02-23 2010-07-06 Novartis Ag p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
MX2007007212A (es) 2004-12-15 2007-11-07 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento del cancer.
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1

Also Published As

Publication number Publication date
WO2007057457A3 (fr) 2008-01-10
CA2933875C (fr) 2018-06-26
NO344288B1 (no) 2019-10-28
AU2010202866A1 (en) 2010-07-29
PL2275103T3 (pl) 2014-09-30
US20080255029A1 (en) 2008-10-16
BRPI0618808A2 (pt) 2011-09-13
AU2006314444C1 (en) 2018-01-04
PT2275103E (pt) 2014-07-24
US20150148294A1 (en) 2015-05-28
EP2022498A3 (fr) 2012-08-15
EP2275103B1 (fr) 2014-04-23
IL253698A0 (en) 2017-09-28
NO346575B1 (no) 2022-10-17
JP5833048B2 (ja) 2015-12-16
EP2275103A2 (fr) 2011-01-19
JP2009516671A (ja) 2009-04-23
CA2629245A1 (fr) 2007-05-24
AU2006314444A1 (en) 2007-05-24
CY1115299T1 (el) 2017-01-04
KR20080071600A (ko) 2008-08-04
CN103446138A (zh) 2013-12-18
NO20170956A1 (no) 2008-08-12
JP2013144706A (ja) 2013-07-25
SI2275103T1 (sl) 2014-07-31
RU2008124827A (ru) 2009-12-27
US20170128425A1 (en) 2017-05-11
CA2629245C (fr) 2016-07-12
NZ568182A (en) 2010-08-27
RU2487711C2 (ru) 2013-07-20
NO20082683L (no) 2008-08-12
HK1150746A1 (en) 2012-01-13
KR20140012218A (ko) 2014-01-29
US9006224B2 (en) 2015-04-14
DK2275103T3 (da) 2014-07-07
EP2275103A3 (fr) 2011-10-12
HRP20140708T1 (hr) 2014-09-26
EP2022498A2 (fr) 2009-02-11
JP2015061868A (ja) 2015-04-02
NO20161045A1 (no) 2008-08-12
ES2481671T3 (es) 2014-07-31
EP1954269A2 (fr) 2008-08-13
CA2933875A1 (fr) 2007-05-24
IL191475A (en) 2017-08-31
JP5963836B2 (ja) 2016-08-03
NO341023B1 (no) 2017-08-07
NO20220050A1 (no) 2008-08-12
WO2007057457A2 (fr) 2007-05-24
IL250697A0 (en) 2017-04-30
AU2006314444B2 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
NL301089I2 (nl) imlifidase
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
TW200714283A (en) Method and composition for treating peripheral vascular diseases
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
IL253698A0 (en) Neuroendocrine tumor treatment has used mTOR inhibitors
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
ITMO20040191A1 (it) Macchina e metodo per il trattamento extracorporeo di sangue.
MXPA05013773A (es) Metodo para elaborar carboxialquilcelulosa.
DE602005013320D1 (de) Carbonitrierter rostfreier martensitischer Einsatzstahl
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
WO2008028963A3 (fr) Utilisation de calréticuline comme médicament pour le traitement d'une maladie telle que le cancer chez un mammifère
NO20072285L (no) S-mirtazapin for behandling av hetetokter
SE0301650D0 (sv) Novel compounds
TNSN07453A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
WO2007053284A3 (fr) Methode de traitement d'un cancer du sein au moyen de 17-aag ou 17-ag ou d'un promedicament d'un de ceux-ci conjointement avec un inhibiteur her2
UA92593C2 (ru) Лечение мастита энрофлоксацином
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
WO2007010013A3 (fr) Composes organiques
RU2004107084A (ru) Способ лечения рецидивирующего птеригиума
WO2007010012A3 (fr) Combinaison de composes organiques
PL1819354T3 (pl) Sposoby i związki do leczenia cukrzycy
WO2009027779A3 (fr) Appareil sanitaire